Is the price fair?
What MDGL's price assumes
Madrigal Pharmaceuticals, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 13.4× revenue.
13.4
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 28.0
Price / book · as of 2026-Q1
- EV / sales
- 13.5
EV / sales
Details›
- Price / book2026-Q1
- 28.0
- EV / EBIToperating margin −25%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 13.5
- Market capitalisation
- $11.7B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.